COMPASS Pathways plc (NASDAQ: CMPS) saw its shares soar 13.55% during intraday trading following the release of its first-quarter 2026 financial results, which exceeded analyst expectations, coupled with significant positive regulatory updates for its lead investigational treatment.

The biotechnology company reported a quarterly loss per share of $(0.30), beating the consensus estimate of $(0.34). Operating income also surpassed forecasts, coming in at a loss of $42.904 million versus an estimated loss of $47.1 million. Investor sentiment was significantly boosted by the announcement that the U.S. Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission and review request for COMP360 (synthetic psilocybin) for treatment-resistant depression, based on positive Phase 3 data.

Further accelerating the regulatory timeline, the company was awarded a Commissioner's National Priority Review Voucher (CNPV), which has the potential to shorten the FDA review process. COMPASS Pathways ended the quarter with a robust cash position of $466 million, which it expects to fund operations into 2028, and remains on track for a final NDA submission in the fourth quarter of 2026.